What biomarker tests are recommended for Endometrial Cancer

Biomarker Testing for Endometrial Cancer

Based on current NCCN Guidelines, biomarker testing plays an important role in understanding your endometrial cancer and guiding treatment decisions. Let me walk you through what tests are typically recommended and why they matter.

The Four Molecular Subtypes

According to NCCN Guidelines, endometrial cancers fall into four clinically significant molecular groups, each with different characteristics and treatment implications:

1. POLE-mutated - Usually high-grade tumors with good prognosis
2. MSI-H (Microsatellite Instability-High) or dMMR (Mismatch Repair Deficient) - Intermediate prognosis
3. NSMP (No Specific Molecular Profile) - Wild-type p53
4. p53 Aberrant - Most aggressive subtype requiring multimodality treatment

---

Recommended Biomarker Tests

CORE MOLECULAR TESTING (Strongly Encouraged)

NCCN Guidelines recommend comprehensive molecular profiling via an FDA-approved assay or validated test performed in a CLIA-certified laboratory. This should include:

1. POLE Gene Testing

• What it detects: Mutations in the DNA polymerase epsilon gene (exonuclease domain)
• Why it matters: POLE mutations typically indicate better prognosis, even in high-grade tumors
• Common mutations: P286R and V411L are the most prevalent

2. Mismatch Repair (MMR) Status

• Testing methods: Immunohistochemistry (IHC) or Microsatellite Instability (MSI) testing
• What it shows: Whether your tumor has defective DNA repair mechanisms
• Clinical significance: MSI-H tumors may respond differently to chemotherapy and immunotherapy
• Important note: If MLH1 loss is found, additional testing for promoter methylation is recommended to determine if it's an epigenetic change or germline mutation

3. p53 Immunohistochemistry (IHC)

• What it detects: Abnormal p53 protein expression
• Why it matters: p53 aberrant tumors are more aggressive and typically require stronger treatment approaches
• Testing requirement: Recommended for all cases to complement morphologic assessment

ADDITIONAL TESTING (Based on Your Situation)

4. HER2 Testing

• Recommended for:
  • All p53 aberrant carcinomas (regardless of histology)
  • All metastatic or recurrent disease
• Method: IHC with reflex to FISH (fluorescence in situ hybridization) if results are equivocal
• Why it matters: HER2 overexpression may open targeted therapy options

5. Estrogen Receptor (ER) and Progesterone Receptor (PR) Testing

• Recommended for:
  • Stage III, IV, or recurrent disease
• Why it matters: ER/PR status helps determine hormone therapy eligibility

6. NTRK and RET Gene Fusion Testing

• Recommended for: Metastatic or recurrent endometrial carcinoma
• Why it matters: These fusions may indicate eligibility for targeted therapies

7. Tumor Mutational Burden (TMB)

• Method: FDA-approved assay or validated CLIA-certified test
• Why it matters: TMB may predict response to immunotherapy

---

When Testing Should Be Done

According to NCCN Guidelines, molecular testing may be performed on:

• Initial biopsy or dilation and curettage (D&C) material
• Final hysterectomy specimen

---

Important Considerations

Genetic Counseling: If you have:

• MMR abnormalities, OR
• A strong family history of endometrial and/or colorectal cancer

You should be referred for genetic counseling and testing to evaluate for Lynch syndrome (hereditary cancer predisposition). This is important because:

• Lynch syndrome increases lifetime endometrial cancer risk up to 60%
• Your relatives may also be at risk
• It affects surveillance and prevention strategies

---

Questions to Ask Your Healthcare Team

1. "Which molecular tests have been performed on my tumor, and what were the results?"
2. "Based on my molecular profile, what treatment options does this open up for me?"
3. "Do my results suggest I should be evaluated for Lynch syndrome or referred for genetic counseling?"
4. "Are there clinical trials available that match my specific molecular subtype?"
5. "How will these biomarker results guide my treatment plan?"

---

Why This Matters

Understanding your tumor's molecular profile helps your oncology team:

• Predict how aggressive your cancer may be
• Determine which treatments are most likely to work
• Identify whether you might benefit from targeted therapies or immunotherapy
• Assess whether clinical trial enrollment might be appropriate
• Evaluate hereditary cancer risk in your family

NCCN Guidelines emphasize that for tumors that are POLE-mutated, MSI-H, p53 aberrant, or NSMP, clinical trial enrollment is strongly encouraged, as research is ongoing to determine the best treatment approaches for each molecular subtype.

---

Important Reminder

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about which tests are appropriate for your specific situation and how results should guide your treatment plan.